The New Era of PCSK9 Inhibitors: Patient Perspectives and Identifying Barriers to Care

Program Overview

This CME activity includes four, 30-minute modules that bring learners up to date on all aspects of treatment and management of patients with dyslipidemia. Dr. Christopher P. Cannon will interview four experts in the field of cardiology. Each module is worth 0.5 CME credits. These modules will explore insights in lowering LDL cholesterol, an analysis of clinical trial data regarding PCSK9 inhibitors and their role in reducing CV risk, and identifying treatment barriers. Each module will enable healthcare providers to walk away with tangible information to better treat their patients.

Target Audience

Cardiologists, internists, and other healthcare professionals involved in the management of patients with dyslipidemia.

Learning Objectives

1. Review the clinical impact of PCSK9 inhibitors in atherosclerotic cardiovascular disease, and identify appropriate patient populations for treatment.
2. Analyze cardiovascular outcomes data for PCSK9 inhibitors and examine its role in reducing cardiovascular risk.
3. Identify financial and other patient-related barriers to care to improve access to PCSK9 inhibitors and optimize cardiovascular outcomes for patients with dyslipidemia.
4. Implement shared decision making into individualized treatment plans to improve the quality of life for patients with dyslipidemia.

Modules

1. Further Insights in Lowering LDL Cholesterol: Managing Atherosclerotic Disease in High-Risk Patients
2. The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics
3. Clinical Trial Analysis of PCSK9 Inhibitors: The Impact of Real-World Cardiovascular Outcomes
4. Identifying Financial and/or Treatment Access Barriers: Patient Perspectives

Chair

Christopher P. Cannon, MD
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Faculty

Michael J. Blaha, MD
Associate Professor of Medicine
Johns Hopkins School of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Baltimore, Maryland

Marc P. Bonaca, MD
Assistant Professor of Medicine, Harvard Medical School
Investigator TIMI Study Group
Cardiology and Vascular Medicine, Brigham and Women’s Hospital
Boston, Massachusetts

Robert P. Giugliano, MD, SM
Senior Investigator, TIMI Study Group
CV Medicine, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

James A. Underberg, MD, MS
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Provider Information

Provided by